In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Brought to you by

Roche, Chugai license Xencor's XmAb to enhance antibodies

Executive Summary

Xencor (engineering antibodies to treat cancer, inflammation, and autoimmune diseases) has licensed Roche and its Japanese affiliate Chugai Pharmaceutical Co. Ltd. individual rights to use its flagship XmAb optimization technology for one year to enhance antibodies against undisclosed cancer targets.

Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Alliance
    • R&D and Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register